|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,030,000 |
Market
Cap: |
903.16(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.48 - $21.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
11 |
Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
9 |
11 |
11 |
12 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Karrels James |
SVP, CFO and Secretary |
|
2018-01-16 |
4 |
OE |
$0.94 |
$6,125 |
D/D |
6,516 |
119,847 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2018-01-16 |
4 |
AS |
$20.00 |
$49,520 |
D/D |
(2,476) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2018-01-16 |
4 |
OE |
$4.70 |
$11,637 |
D/D |
2,476 |
32,476 |
|
- |
|
Karrels James |
SVP, CFO and Secretary |
|
2017-12-29 |
4 |
OE |
$0.94 |
$2,820 |
D/D |
3,000 |
113,331 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-11-21 |
4 |
AS |
$20.00 |
$100,000 |
D/D |
(5,000) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-11-21 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
35,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-10-25 |
4 |
AS |
$20.00 |
$200,000 |
D/D |
(10,000) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-10-25 |
4 |
OE |
$4.70 |
$47,000 |
D/D |
10,000 |
40,000 |
|
- |
|
Risser Eric Blasius |
Sr VP & Chief Business Officer |
|
2017-09-05 |
4 |
OE |
$0.94 |
$1,880 |
D/D |
2,000 |
6,000 |
|
- |
|
Karrels James |
SVP, CFO and Secretary |
|
2017-09-05 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
110,331 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2017-07-26 |
4 |
OE |
$0.94 |
$65,248 |
D/D |
53,264 |
146,658 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-06-05 |
4 |
AS |
$20.00 |
$100,000 |
D/D |
(5,000) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-06-05 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
35,000 |
|
- |
|
Saran Atul |
SVP & General Counsel |
|
2017-04-28 |
4 |
D |
$21.61 |
$40,238 |
D/D |
(1,862) |
16,986 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-04-19 |
4 |
AS |
$20.00 |
$300,000 |
D/D |
(15,000) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2017-04-19 |
4 |
OE |
$4.70 |
$70,500 |
D/D |
15,000 |
45,000 |
|
- |
|
Karrels James |
SVP, CFO and Secretary |
|
2017-01-25 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
105,331 |
|
- |
|
Koenig Scott |
President and CEO |
|
2017-01-17 |
4 |
OE |
$0.94 |
$75,104 |
D/D |
79,898 |
133,163 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2016-10-19 |
5 |
OE |
$0.94 |
$5,028 |
D/D |
5,349 |
93,394 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2016-10-19 |
4 |
OE |
$0.94 |
$5,028 |
D/D |
5,349 |
100,944 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2016-10-03 |
5 |
S |
$29.34 |
$293,400 |
D/D |
(10,000) |
30,000 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2016-10-03 |
4 |
AS |
$29.34 |
$293,400 |
D/D |
(10,000) |
0 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
|
2016-10-03 |
4 |
OE |
$4.70 |
$47,000 |
D/D |
10,000 |
10,000 |
|
- |
|
Cilinski Lynn |
VP, Controller and Treasurer |
|
2016-10-03 |
4 |
AS |
$29.28 |
$182,444 |
D/D |
(6,231) |
1,923 |
|
- |
|
Cilinski Lynn |
VP, Controller and Treasurer |
|
2016-10-03 |
4 |
OE |
$0.94 |
$5,857 |
D/D |
6,231 |
8,154 |
|
- |
|
286 Records found
|
|
Page 7 of 12 |
|
|